|
|
|
|
Ripretinib |
|
Evaluate the Efficacy and Safety of Radiotherapy Combined With Ripretinib in the Treatment of Unresectable Advanced GIST |
NA |
| |
|
|
|
DCC-3009 |
|
A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST) |
1/2 |
| |
|
|
|
DCC-3116 + Ripretinib |
|
A Study of DCC-3116 in Combination with Anticancer Therapies in Participants with Advanced Malignancies |
1/2 |
| |
|
|
|
Bezuclastinib plus Sunitinib |
|
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors |
3 |
| |
|
|
|
Famitinib |
|
Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib |
3 |
| |
|
|
|
Olverembatinib |
|
A Study of Olverembatinib in SDH-deficient GIST. (POLARIS-3) |
3 |
| |
|
|
|
Ripretinib |
|
A Phase 3 Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib (INSIGHT) |
3 |
| |
|
|
|
Avelumab + Axitinib |
|
A Study of Avelumab In Combination With Axitinib in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumor After Failure of Standard Therapy (AXAGIST) |
2 |
| |
|
|
|
Bezuclastinib plus Sunitinib |
|
SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST |
2 |
| |
|
|
|
ctDNA plus Sunitinib or Regorafenib |
|
ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST |
2 |
| |
|
|
|
Imatinib |
|
Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten) |
2 |
| |
|
|
|
Imatinib |
|
Imatinib TDM (Therapeutic Drug Monitoring) in GIST |
2 |
| |
|
|
|
Imatinib |
|
Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors (ZJGIST-01) |
2 |
| |
|
|
|
Imatinib |
|
5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk |
2 |
| |
|
|
|
Imatinib + Atezolizumab |
|
A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments (ATEZOGIST) |
2 |
| |
|
|
|
Lenvatinib |
|
Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure (LENVAGIST) |
2 |
| |
|
|
|
Paclltaxel |
|
Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib. |
2 |
| |
|
|
|
Regorafenib |
|
Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting. |
2 |
| |
|
|
|
Regorafenib + Envafolimab |
|
A Study of Regorafenib Combined with Envafolimab for Metastatic Gastrointestinal Stromal Tumors with Kit Gene Exon 17 Mutation That Failed Standard Treatment |
2 |
| |
|
|
|
IDRX-42 |
|
A First-in-human (FIH) Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) [Study ID: StrateGIST1] |
1 |
| |
|
|
|
Pimitesib |
|
A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101) |
1 |
| |
|
|
|
Apatinib Mesylate |
|
Apatinib Mesylate (Rivoceranib) Versus Standard Second-line TKI in the Treatment of Advanced GIST |
|
| |
|
|
|
Imatinib + Sunitinib + Regorafenib |
|
GIST: Assessment of Tumor Mutations and TKI Plasma Exposure |
|
| |
|
|
|
Ripretinib |
|
Ripretinib Used for Resectable Metastatic GIST After Failure of Imatinib Therapy |
|
| |
|
|
|
Surgery |
|
Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis |
|
| |
|
|
|
neoBOMB1 |
|
[177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-NeoB Lesion Uptake (NeoRay) |
1/2 |
| |
|
|
|
Regorafenib + Avelumab |
|
A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE) |
1/2 |
| |
|
|
|
Belzutifan |
|
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015) |
2 |
| |
|
|
|
HQP1351 |
|
A Study of HQP1351 in Patients With GIST or Other Solid Tumors |
1 |
| |
|
|
|
INBRX-109 + Temozolomide |
|
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas |
1 |
| |
|
|
|
NB003 |
|
A Study of NB003 in Patients With Advanced Malignancies |
1 |
| |
|
|
|
NN3201 |
|
A Study of the C-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced And/or Metastatic Solid Tumors Known to Express C-Kit |
1 |
| |
|
|
|
MRTX1719 |
|
Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion |
1/2 |
| |
|
|
|
